Novo Nordisk A/S Chairman Lars Rebien Sorensen will face a hostile investor meeting on Thursday, marking his first public address since seizing board control in a contentious coup. The gathering, held at the company’s Copenhagen headquarters, will test his ability to quell mounting skepticism over strategic direction and financial transparency. Investors, who ousted his predecessor in 2023 over governance concerns, are expected to demand clearer communication on drug pipeline progress and cost-cutting measures.

The boardroom coup, which saw Sorensen replace two senior executives last month, has deepened tensions between management and shareholders. While Novo’s diabetes care division remains a market leader, rivals like Eli Lilly and Sanofi are aggressively expanding in obesity and GLP-1 therapies—segments where Novo’s pipeline lags. Analysts suggest the meeting could signal whether Sorensen’s leadership will prioritize innovation or short-term profitability to satisfy investors.

Novo Nordisk’s stock, trading at $142 per share, has underperformed peers this year amid questions about its ability to scale breakthrough treatments. Shareholders will scrutinize Sorensen’s plans to allocate resources between high-risk research and lucrative blockbuster drugs. A lack of concrete answers risks prolonging shareholder unrest and triggering governance reforms.

This confrontation underscores broader challenges for pharmaceutical giants balancing R&D investments with shareholder returns. For Novo, a company valued at $320 billion, the outcome may determine its competitiveness in a rapidly evolving healthcare market. Investors will leave Thursday’s meeting with heightened expectations for transparency—or greater impatience for results.